<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> cell populations have been recently proposed to be composed of two compartments: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-initiating cells characterized by a slow and asymmetrical growth, and the "differentiated" <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells with a fast and symmetrical growth </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> stem cells or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-initiating cells (CICs) play a crucial role in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence </plain></SENT>
<SENT sid="2" pm="."><plain>The resistance of CICs to drugs and irradiation often allows them to survive traditional therapy </plain></SENT>
<SENT sid="3" pm="."><plain>NK cells are potent cytotoxic lymphocytes that can recognize <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we have analyzed the NK cell recognition of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> target cells derived from the two <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell compartments of <z:mp ids='MP_0009314'>colon adenocarcinoma</z:mp> lesions </plain></SENT>
<SENT sid="5" pm="."><plain>Our data demonstrate that freshly purified allogeneic NK cells can recognize and kill colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp>-derived CICs whereas the non-CIC counterpart of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (differentiated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells), either autologous or allogeneic, is less susceptible to NK cells </plain></SENT>
<SENT sid="6" pm="."><plain>This difference in the NK cell susceptibility correlates with higher expression on CICs of ligands for NKp30 and NKp44 in the natural cytotoxicity receptor (NCR) group of activating NK receptors </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, CICs express lower levels of MHC class I, known to inhibit NK recognition, on their surface than do the "differentiated" <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>These data have been validated by confocal microscopy where NCR ligands and MHC class I molecule membrane distribution have been analyzed </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, NK cell receptor blockade in cytotoxicity assays demonstrates that NCRs play a major role in the recognition of CIC targets </plain></SENT>
<SENT sid="10" pm="."><plain>This study strengthens the idea that biology-based therapy harnessing NK cells could be an attractive opportunity in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
</text></document>